US20190247420A1 - Compounds and methods for reducing atxn3 expression - Google Patents

Patent application publication

Physiological and pathophysiological characteristics of ataxin-3 isoforms - ScienceDirect

TW202113082A - Antisense oligonucleotides targeting atxn3 - Google Patents

Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein - ScienceDirect

WO2017143291A1 - METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION - Google Patents

TW202113082A - Antisense oligonucleotides targeting atxn3 - Google Patents

US20190247420A1 - Compounds and methods for reducing atxn3 expression - Google Patents

ATXN3 Gene - GeneCards, ATX3 Protein

US20170175113A1 - Methods for modulating ataxin 2 expression - Google Patents

Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein - ScienceDirect

Tissue expression of ATXN3 - Summary - The Human Protein Atlas

WO2020006018A1 - Substituted naphthyridinone compounds useful as t cell activators - Google Patents

Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein - ScienceDirect

US20170175113A1 - Methods for modulating ataxin 2 expression - Google Patents

US8883805B2 - Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines - Google Patents

US7612114B2 - Selective estrogen receptor modulator - Google Patents